LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Faisal A. Al-Allaf1, Charles Coutelle2,3,4,5,6,7,8, Simon N. Waddington2,3,4,8,7,6,5, Anna L. David3,5,8,6,7,4,2, Richard P. Harbottle2,3,4,5,8,6,7, Michael Themis2,4,5,8,6,7,3
1Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Al-Abedia Campus, P. O. Box 715, Makkah 21955, Saudi Arabia
2Gene Therapy Research Group, Department of Molecular and Cell Medicine, Sir Alexander Fleming Building,
3Group Leader, Gene Therapy and Genotoxicity Research Group, Brunel University, Heinz Wolff Building, Uxbridge, Middlesex, West London UB8 3PH, UK.
4Gene Therapy Group Leader in the Section of Molecular Medicine in the Sir Alexander Fleming Building, NHLI, Imperial College London, London SW7 2AZ, UK. A.
5Obstetrics and Maternal/Fetal Medicine, and leads the Prenatal Cell and Gene Therapy Group, Institute for Women's Health, University College London and UCLH, 86-96 Chenies Mews, London, WC1E 6HX, UK.
6Professor of Genetics and Molecular Medicine,
7Group Leader, Prenatal Gene Therapy Research Group, Department of Haematology, Haemophilia Centre and Haemostasis Unit, Royal Free and University College Medical School, London NW3 2PF, UK.
8Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, Al-Abedia Campus, Makkah 21955, Saudi Arabia.
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
International Medical Publisher (Fundacion de Neurociencias)
Thông tin tác giả